BlossomHill Therapeutics
SAN DIEGO, CA · Biotechnology, Healthcare, Health Care · 55 employees
BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders. The company is founded by renowned drug design and development scientist, J. Jean Cui, Ph.D., and biotech business veteran, Y. Peter Li, Ph.D., M.B.A. BlossomHill Therapeutics, Inc. is headquartered in San Diego, California.
Funding history
- Venture - Series Unknown — $84.2M — Dec 2025
- Series B — $100.0M — Feb 2024
- Venture - Series Unknown — $88.6M — Jan 2024
- Venture - Series Unknown — $71.0M — Mar 2021
- Venture - Series Unknown — $2.0M — Jan 2021
Recent signals
- Dec 10, 2025: Raised $84.2M in Venture - Series Unknown
- May 09, 2025: BlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer
- Jan 22, 2025: Launched BlossomHill Therapeutics Doses First Cohort of Patients in Phase 1/2 Clinical Trial for BH-30643 Targeting Lung Cancer.
- Jan 06, 2025: BlossomHill Therapeutics Appoints Geoff Oxnard as Chief Medical Officer and Executive Vice President, and Ashley Preston as Senior Vice President and Head of Regulatory Affairs and Quality Assurance
- Feb 29, 2024: Raised $100.0M in Series B
- Jan 02, 2024: Raised $88.6M in Venture - Series Unknown
- Mar 01, 2021: Raised $71.0M in Venture - Series Unknown
- Jan 11, 2021: Raised $2.0M in Venture - Series Unknown
See plans & pricing → Track BlossomHill Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.